Ti Angeline, Stone Rebecca H, Whiteman Maura, Curtis Kathryn M
Division of Reproductive Health, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S107-2, Atlanta, GA 30341, United States; Departments of Gynecology and Obstetrics, and Family and Preventive Medicine, Emory University School of Medicine, 49 Jesse Hill Jr Dr SE, Atlanta, Georgia 30303, United States.
College of Pharmacy, University of Georgia, Athens, Georgia, United States.
Contraception. 2019 Dec;100(6):480-483. doi: 10.1016/j.contraception.2019.08.006. Epub 2019 Sep 1.
To systematically review the literature around the safety and effectiveness of hormonal contraception for women who use opioids. Our specific research questions are: 1) Among women who use opioids, do those who use hormonal contraception have increased adverse health events compared with those who do not use hormonal contraception? 2) Are there drug interactions between hormonal contraception and opioids that cause decreased effectiveness or increased toxicity from either drug?
We searched Medline, Embase, PsychInfo, CINAHL, the Cochrane Library, and clinicaltrials.gov through August 2018. We considered randomized controlled trials, cohort studies, and case-control studies, as well as pharmacokinetic and pharmacodynamic studies. We planned to use standard frameworks to assess risk of bias of included studies.
The search identified 1852 articles. The full text of 66 articles was reviewed, and none met inclusion criteria.
Because we found no direct evidence on the safety and effectiveness of hormonal contraception for women who use opioids, we considered theoretical concerns. While women with OUD have a high prevalence of co-morbidities, such as viral hepatitis, generally women with medical conditions can safely use most contraceptive methods. When considering the pharmacokinetics and pharmacodynamics of hormonal contraception and opioids, there is little theoretical concern for interactions. Therefore, future research efforts could focus on improving access to the full range of contraceptive methods for women who use opioids, reducing unnecessary barriers to initiating and using contraception, while ensuring voluntary choice related to contraceptive use.
系统回顾关于使用阿片类药物的女性使用激素避孕的安全性和有效性的文献。我们的具体研究问题是:1)在使用阿片类药物的女性中,与未使用激素避孕的女性相比,使用激素避孕的女性是否有更多不良健康事件?2)激素避孕与阿片类药物之间是否存在药物相互作用,导致其中任何一种药物的有效性降低或毒性增加?
我们检索了截至2018年8月的Medline、Embase、PsychInfo、CINAHL、Cochrane图书馆和clinicaltrials.gov。我们纳入了随机对照试验、队列研究、病例对照研究以及药代动力学和药效学研究。我们计划使用标准框架来评估纳入研究的偏倚风险。
检索到1852篇文章。对66篇文章的全文进行了审查,没有一篇符合纳入标准。
由于我们没有找到关于使用阿片类药物的女性使用激素避孕的安全性和有效性的直接证据,我们考虑了理论上的问题。虽然患有阿片类药物使用障碍的女性合并症患病率很高,如病毒性肝炎,但一般来说,患有疾病的女性可以安全地使用大多数避孕方法。考虑到激素避孕和阿片类药物的药代动力学和药效学,理论上几乎不存在相互作用的担忧。因此,未来的研究工作可以集中在改善使用阿片类药物的女性获得全面避孕方法的机会上,减少启动和使用避孕措施的不必要障碍,同时确保与避孕使用相关的自愿选择。